Sanofi wins approval for first Bruton’s tyrosine kinase inhibitor in immune thrombocytopenia
1. The FDA approved rilzabrutinib, branded Wayrilz, as the first BTK (Bruton’s tyrosine kinase) inhibitor for adults with ITP (immune ...
Tag: rilzabrutinib
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)
2 Minute Medicine: Pharma Roundup- Obesity RNA deal, at-home Alzheimer’s dosing, oncology royalty financing, and first Bruton’s Tyrosine Kinase Inhibitor for Immune Thrombocytopenia [September 3, 2025]
Novo’s srRNA push expands cardiometabolic pipeline On August 28, Novo Nordisk announced a collaboration with Replicate Bioscience to pursue self ...
Rilzabrutinib demonstrates rapid and durable clinical activity for immune thrombocytopenia
1. Rilzabrutinib was active and 400mg twice daily was identified as the dose for further testing with low-level toxic effects. ...
